About
Technology
Issues
FAQ
Links
Official Page
Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.